Table 1.
Males n = 57 |
Females n = 53 |
p value | |
---|---|---|---|
Age (years) | 72.2 ± 6.5 | 71.9 ± 6.9 | NS |
WBC (103/μL) | 6.3 ± 1.7 | 6.4 ± 1.3 | 0.02 |
Lymphocytes (%) | 29.6 ± 7.6 | 32.3 ± 6.7 | 0.044 |
Neutrophils (%) | 58.4 ± 8.1 | 53.7 ± 5.8 | 0.002 |
Monocytes (%) | 7.2 ± 1.5 | 7.0 ± 1.8 | NS |
Erythrocytes (106/μL) | 4.9 ± 0.4 | 4.5 ± 0.4 | 0.001 |
Hemoglobin (g/dL) | 15.2 ± 1.2 | 14.1 ± 1.2 | 0.001 |
AST (U/L) | 25.0 ± 6.8 | 21.8 ± 8.4 | 0.036 |
ALT (U/L) | 33.0 ± 11.9 | 30.3 ± 13.1 | NS |
Creatinine (mg/dL) | 1.02 ± 0.18 | 0.88 ± 0.2 | 0.001 |
CRP (pg/mL) | 0.48 ± 0.69 | 0.36 ± 0.31 | NS |
Albumin (g/dL) | 4.1 ± 0.24 | 4.0 ± 0.22 | 0.047 |
Glycemia (mg/dL) | 96.8 ± 11.0 | 96.4 ± 14.6 | NS |
TG (mg/dL) | 119.4 ± 59.6 | 131.9 ± 55.2 | NS |
TC (mg/dL) | 211.4 ± 28.2 | 233.5 ± 45.6 | 0.001 |
HDL-C (mg/dL) | 48.5 ± 28.2 | 55.5 ± 16.4 | 0.008 |
AGEs (ng/mL) | 1.51 ± 0.63 | 1.34 ± 0.56 | 0.166 |
ROS (MFI) | 15.3 ± 12.6 | 12.0 ± 11.8 | 0.201 |
pSOD (U/mL) | 21.74 ± 3.34 | 21.13 ± 2.60 | 0.367 |
GPx (nmol NADPH/min/mL) | 0.099 ± 0.004 | 0.100 ± 0.007 | 0.930 |
CAT (μmol/min/mg prot) | 21.47 ± 2.61 | 21.07 ± 2.97 | 0.528 |
Zn plasma levels (μM) | 10.67 ± 2.39 | 10.85 ± 2.45 | 0.734 |
Zn granulocytes (nmol/mg protein) | 0.21 ± 0.13 | 0.20 ± 0.11 | 0.718 |
MT (MFI) | 98.2 ± 40.8 | 82.5 ± 31.2 | 0.161 |
iZnL | 1.24 ± 0.10 | 1.29 ± 0.10 | 0.035; 0.070a |
iZnR | 0.17 ± 0.04 | 0.18 ± 0.09 | 0.410 |
Zinc score | 130 ± 57 | 121 ± 51 | 0.020; 0.030a |
Data are mean ± SD
WBC white blood cells, AST aspartate aminotransferase, ALT alanine aminotransferase, CRP C-reactive protein, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, AGEs advanced glycation end-products, ROS reactive oxygen species, pSOD plasma superoxide dismutase, GPx glutathione peroxidase, CAT catalase, MT metallothioneins, iZnL intracellular labile zinc, NO-iZnR-induced release of zinc
aComparisons between males and females were performed by ANCOVA analysis adjusting for age and country and lipid profile